Idelalisib study evaluates CLL treatment on older patients

Gilead announced Phase 2 results for idelalisib, an oral inhibitor of PI3K delta in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia.

Adcetris being reviewed for retreatment, extended duration therapy

The FDA has accepted Seattle Genetics' sBLA for filing of Adcetris for retreatment and extended duration beyond 16 cycles of therapy in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

Experts aim to draw attention to high cancer drug costs

Leukemia experts call for examination of the 'right' way to price life-saving drugs

In CNL and Atypical CML, mutations in CSF3R are common

For patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, activating mutations in the gene encoding the colony stimulating factor 3 receptor are common.

Monoclonal antibody kills leukemia cells

A monoclonal antibody has been found to be cytotoxic to chronic lymphocytic leukemia B cells while having little effect on normal B cells.

Chronic fatigue more common after childhood leukemia, lymphoma

Chronic fatigue is more than three times more prevalent among adult survivors of childhood leukemia or lymphoma than among other adults.

Engineered T cells help patients with relapsed B-ALL acheive remission

Treatment with autologous engineered T cells is effective bridge to potentially curative therapy

Mer inhibition may be key to enhanced leukemia treatment

Inhibiting the protein receptor Mer destroys cancer cells and enhances chemotherapy in both acute myeloid and acute lymphoblastic leukemia.

Clinical Trial: Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water

Clinical Trial: Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia

Clinical Trial: Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)